However, our data suggest that in AS when GLP1 mono agonists do not lead to sustained weight loss, a switch to the dual GIP/GLP1 agonist tirzepatide should be considered, especially when obesity-related comorbidities are present. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.